Understanding of this pathway has created a viable therapeutic opportunity [22], and molecular targeting of Hsp90 ATPase activity by the class of ansamycin antibiotics prototypically exemplified by geldanamycin [23] has shown promising anticancer activity by disabling multiple signaling networks required for tumor-cell maintenance [24]. The gene discussed is HSP90AA1; the disease is neoplasm.